The content on this site is intended for healthcare professionals only
Dr Luis Paz-Ares speaks to ecancer about the groundbreaking impact of T-cell engagers in treating small cell lung cancer (SCLC).
He details the impressive response rates and survivorship achieved so far in early phase trials and looks at how this innovative therapy activates the immune system, offering new hope for patients, particularly those with challenging SCLC presentations.
He concludes by noting that T-cell engagers are important for SCLC where very often there is a down regulation of MHC (Major Histocompatibility Complex) class 1. Therefore, it is a good mechanism for tumours where there is no initial T-cell activation.
Concurrent thoracic radiotherapy plus chemo-ICI shows no overall survival benefit in ES-SCLC
Denikitug shows immune activation and early anti-tumour activity in advanced solid tumour
Immunoprevention and early detection of lung cancer in Africa: The LUNG-GUARD Platform
Zongertinib shows high response rates in first-line HER2-mutant advanced NSCLC
Nivolumab plus ipilimumab improves survival results in MSI-H/dMMR metastatic colorectal cancer
Pembrolizumab plus cCRT continue to demonstrate antitumour activity in advanced NSCLC
TAR-200 plus cetrelimab show encouraging outcomes for MIBC patients ineligible for standard cisplatin-based chemotherapy
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC
Uncommon genetic aberrations NTRK, RET, NRG
